Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Szer, Jeff  [Clear All Filters]
2024
McQuilten Z, Heritier S, Fox L, Fox V, Young L, Blombery P, Cunningham I, Curnow J, Higgins A, Hiwase DK, et al. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials. BMJ Open. 2024;14(1):e076246.
de Latour RPeffault, Griffin M, Kelly RJ, Szer J, de Castro C, Horneff R, Tan L, Yeh MM, Panse JPeter. Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2024.
2023
Tew M, Douglas AP, Szer J, Bajel A, Harrison SJ, Tio SYen, Worth LJ, Hicks RJ, Ritchie D, Slavin MA, et al. Evaluating the cost-effectiveness of [F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients. Cancer Imaging. 2023;23(1):119.
McErlean G, Bajel A, Bhattacharyya A, Brown N, Lourenco RDe Abreu, Greenwood M, Kerridge I, Kim N, Kliman D, Maneze D, et al. If we do not count it, it does not count: ethnicity in allogeneic haemopoietic stem cell transplant in Australia. Intern Med J. 2023.
Terriou L, Lee JWook, Forsyth C, Griffin M, Szer J, Röth A, Gustovic P, Metzger J, Patel AS, Patriquin CJ. Long-term effectiveness of eculizumab: Data from the International PNH Registry. Eur J Haematol. 2023.
2022
Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBc, Kröger N, Mohty M, Galeano S, Okamoto S, et al. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.
Douglas A, Thursky K, Spelman T, Szer J, Bajel A, Harrison S, Tio SYen, Bupha-Intr O, Tew M, Worth L, et al. [F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Haematol. 2022.
de Latour RPeffault, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian J-J, de Castro CM, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9(9):e648-e659.
Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, et al. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. Lancet Haematol. 2022;9(8):e605-e614.
Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, et al. WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplant Cell Ther. 2022.
2021
Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian J-J, de Castro C, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021;384(11):1028-1037.
2020
Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transplant. 2020.
Douglas AP, Yu L, Sundararajan V, Szer J, Ritchie D, Slavin MA, Sasadeusz J, Visvanathan K. The QuantiFERON Monitor Assay is predictive of infection post allogeneic hematopoietic cell transplant. Transpl Infect Dis. 2020:e13260.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020.
Szer J. Is there no place like home for an allogeneic stem cell transplant?. Bone Marrow Transplant. 2020.
2019
Curran D, Matthews S, Rowley SD, Young J-AH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PHaran, Dickinson M, Idrissi MEl, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019.
2016
Yoshimi A, Baldomero H, Horowitz M, Szer J, Niederwieser D, Gratwohl A, Kodera Y. Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. JAMA. 2016;315(2):198-200.
Szer J, Elmoazzen H, Fechter M, Hwang W, Korhonen M, Miller J, Mengling T, Shaw B, Stein J. Safety of Living Donation of Hematopoietic Stem Cells. Transplantation. 2016.
2014
Lim ABM, Roberts AW, Mason K, Bajel A, Szer J, Ritchie DS. Validating the Allogeneic Stem Cell Transplantation Disease Risk Index: Sample Size, Follow-up, and Local Data Are Important. Transplantation. 2014.